NTRK1 and cancer: These oncogenic properties together with the capacity of GLI1 to integrate and relay common SMO-independent cancer-promoting cues such as receptor-tyrosine kinase pathways, PI3K and MAP kinase signaling render GLI1 an attractive molecular target for cancer therapy.